Century Therapeutics: A Promising Player in the Type I Diabetes Mellitus Functional Cure Race

lunes, 9 de febrero de 2026, 11:24 am ET1 min de lectura
IPSC--

Century Therapeutics is developing iPSC-derived therapies for type I diabetes mellitus, autoimmune diseases, and oncology indications. Their iPSC platform enables scalable and homogeneous production of cell therapies. The company is a promising contender in the functional cure race for T1DM.

Century Therapeutics: A Promising Player in the Type I Diabetes Mellitus Functional Cure Race

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios